Loading
CCNE2 (G1/S-specific cyclin-E2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.
Essential for the control of the cell cycle at the late G1 and early S phase.
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Palbociclib and CDK Inhibitor SNS-032.
In plain words · CCNE2 (G1/S-specific cyclin-E2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.
CCNE2 (G1/S-specific cyclin-E2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.
Essential for the control of the cell cycle at the late G1 and early S phase. Location: Nucleus (UniProt).
No product in this corpus aims at CCNE2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA CCNE2: RNA tissue enhanced (bone marrow 35 nTPM, brain 17 nTPM); no normal tissue stained high; highest cancer staining carcinoid (1 of 4 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Breast cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas CCNE2 tissue; Open Targets ENSG00000175305 associations
First described 1998. Earliest sequence paper UniProt cites for the protein: Lauper et al, Oncogene, 1998, "Cyclin E2: a novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle". Source.
Sources: HGNC HGNC:1590 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O96020 (protein name, function text, keywords and locations (REST API)); CIViC gene CCNE2 (2 evidence items, 0 assertions, 1 variants; diseases: Breast Cancer (GraphQL API, CC0))
Essential for the control of the cell cycle at the late G1 and early S phase. Location: Nucleus (UniProt). Locus 8q22.1 (HGNC).
RNA: tissue enhanced (bone marrow 35 nTPM, brain 17 nTPM), detected in many normal tissues.
No normal tissue stained high; medium in Appendix, Bone marrow, Caudate, Cerebellum, Cerebral cortex, Lymph node and more.
Medium only: breast cancer, glioma, head and neck cancer, liver cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CCNE2" OR ABSTRACT:"CCNE2" OR TITLE:"cyclin E2" OR ABSTRACT:"cyclin E2" OR TITLE:"G1/S-specific cyclin-E2" OR ABSTRACT:"G1/S-specific cyclin-E2" OR TITLE:"CYCE2" OR ABSTRACT:"CYCE2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CCNE2, not a curated reading list.